NDC product
Gvoke VialDx
NDC 0517-2901 · American Regent, Inc.
Key facts
| Product NDC | 0517-2901 |
|---|---|
| Proprietary name | Gvoke VialDx |
| Nonproprietary name | glucagon injection |
| Substances | GLUCAGON |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Labeler | American Regent, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA212097 |
| Pharmacologic classes | Antihypoglycemic Agent [EPC], Decreased GI Motility [PE], Decreased GI Smooth Muscle Tone [PE], Decreased Glycolysis [PE], Gastrointestinal Motility Inhibitor [EPC], Increased Gluconeogenesis [PE] and 1 more |
| Marketing start | Aug 19, 2025 |
| Marketing end | Sep 30, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory